Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BD

Published: Wednesday, June 23, 2010
Last Updated: Wednesday, June 23, 2010
Bookmark and Share
BD will use Exiqon's proprietary LNA™ technology in defined products for infectious disease diagnostics.

Exiqon A/S has announced that it has granted a non-exclusive license to BD (Becton, Dickinson and Company) to use Exiqon's proprietary locked nucleic acids (LNA™) technology in defined products for infectious disease diagnostics.

Exiqon will receive upfront and milestone payments, and royalty on global sales of the products covered by this agreement. Financial terms of the agreement were not disclosed.  The U.S. DNA-based infectious diseases testing market is estimated by Frost and Sullivan to exceed $2 billion in 2010. This agreement marks the first time LNA™ will be applied in the development of FDA-cleared diagnostic products.

“We are pleased to see BD has chosen to apply Exiqon's proprietary technology enabling these exciting new diagnostic products,” said Lars Kongsbak, CEO & President of Exiqon. ”We are excited that the LNA™ technology is now being applied to advanced diagnostic products.”

Under the terms of this agreement, BD will market a number of defined LNA™-enhanced products to run on the new BD MAX™ System, BD's next-generation platform for molecular diagnostics based on real-time polymerase chain reaction.

LNA™ offers many potential enhancements for developing advanced products. An inherent part of Exiqon's strategy to capitalize on its proprietary LNA™ technology is through license agreements within market segments that Exiqon does not plan to pursue itself.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exiqon Secures Funding to Accelerate Growth
Exiqon A/S has announced the issue of a senior secured note in the amount of DKK 40 million (‘Note’).
Thursday, November 12, 2015
Exiqon Launches New LNA™ Antisense Oligonucleotides for RNA Functional Analysis
These new products offer a powerful alternative to existing siRNAs already on the market place.
Tuesday, May 26, 2015
Exiqon Licenses Biomarkers From Aarhus University Hospital
Exiqon A/S has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus University Hospital, Department of Molecular Medicine (MOMA).
Wednesday, December 03, 2014
Redefining High Risk Patients With Stage II Colon Cancer
microRNA-21 identified as an independent prognostic biomarker.
Friday, September 12, 2014
Exiqon Awarded Global microRNA Research Tools Company of the Year
Company has been recognized as the recipient of the award in light of the excellence that Exiqon has exhibited in the microRNA research space.
Monday, July 08, 2013
Exiqon and Asuragen Sign Agreement for Real-Time PCR Services
The Service Center Agreement allows Asuragen to provide real-time PCR services based on Exiqon’s miRCURY LNA™ Universal RT microRNA PCR products.
Tuesday, June 11, 2013
Exiqon Announces 2011 Grant Program for MicroRNA Research
Company announces the launch of 2011 global research grant program, open to researchers from academic and non-profit institutions.
Wednesday, February 02, 2011
Exiqon and MultiD Sign Development and Distribution Agreement for microRNA qPCR Analysis Solution
Agreement incorporates a specifically adapted version of the GenEx qPCR analysis software for Exiqon's new microRNA qPCR platform.
Wednesday, May 26, 2010
Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
ICCB-L will provide the Exiqon LNA™ microRNA Knockdown Library as a screening tool for a new consortium of Harvard-affiliated investigators.
Tuesday, December 01, 2009
Exiqon partners with MedTrust Online to Promote Molecular Oncology Diagnostic Services to Oncologists
Exiqon will provide a comprehensive suite of oncology molecular diagnostics services to MedTrust Online's Oncocentric oncology portal.
Wednesday, June 03, 2009
Exiqon Expands in US; Sales Headquarters Established
Establishing a US presence will liberate resources at the existing Danish facility to focus on sales opportunities in Europe and Asia.
Thursday, September 14, 2006
Exiqon Appoints President and General Manager of new US Operations
Michael Kallelis will have the overall responsibility for launching and operating Exiqon’s US office to be located in the Boston area.
Friday, January 06, 2006
Exiqon Wins Ernst & Young Entrepeneur of the Year Award
Exiqon selected as winner in the BIOTECH 2005 category.
Tuesday, November 22, 2005
Exiqon A/S appoints permanent CEO

Monday, February 24, 2003
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos